Your session is about to expire
← Back to Search
Other
TRPV6 Calcium Channel Inhibitor SOR-C13 for Pancreatic Cancer
Phase 1
Waitlist Available
Led By Siqing Fu
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
Summary
This trial examines the side effects and optimal dose of SOR-C13 in patients with advanced solid tumors that have not responded to other treatments. SOR-C13 aims to block a pathway in cancer cells to prevent their growth and spread.
Eligible Conditions
- Pancreatic Cancer
- Ovarian Cancer
- Prostate Cancer
- Solid Tumors
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of adverse events and serious adverse events
Secondary study objectives
Clinical benefit
Objective responses
Predictive biomarkers
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (TRPV6 calcium channel inhibitor SOR-C13)Experimental Treatment1 Intervention
Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SOR-C13
Not yet FDA approved
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,045 Previous Clinical Trials
1,800,073 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,868 Previous Clinical Trials
41,010,826 Total Patients Enrolled
Siqing FuPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
531 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger